Guardant Health: Due For A Rally

About: Guardant Health, Inc. (GH)
by: BioSci Capital Partners
This article is exclusive for subscribers.

For the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181% (i.e. at $60.8M).

The bottom line earnings also improved by the remarkable 92.7%. If Guardant can maintain this momentum, it will generate positive cash flow within the next two to three years.

Amid these advancements, I believe that there's a high probability that another rally is due for either this year or early next year.

In the foreseeable future, will the growth of the company require sufficient equity financing so that the larger number of shares outstanding will largely cancel the existing stockholders' benefit from this anticipated growth? - Phillip